Thalidomide gets a second chance in Japan
This article was originally published in Scrip
An advisory committee to Japan's ministry of health, labour and welfarehas recommended the approval of thalidomide for the treatment of refractory multiple myeloma, providing a new opportunity to a product banned in the country in 1962.
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.